Chronic myeloid leukemia: Current treatment options

Blood

Volumn 98, Issue 7, 2001, Pages 2039-2042

  Goldman, John M ^a,b,c   Druker, Brian J ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTILEUKEMIC AGENT; CYTARABINE; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG USE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0035496899     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.7.2039     Document Type: Review

References (17)

1. Barrett AJ, Malkovska V. Graft-versus-leukaemia: understanding and using the allo-immune response to treat haematological malignancies. Br J Haematol. 1996;93:754-761.
2. Sinclair PB, Nacheva EP, Levasha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis sub-group of patients with chronic myeloid leukemia. Blood. 2000;95:738-744.
3. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883-1890.
4. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. Blood. 1984;63:789-799.
5. Hasford J, Pfirrmann J, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850-858.
6. Mahon F, Faberes C, Pueyo S, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated with recombinant interferon-α. Blood. 1998;92:4059-4065.
7. Goldman JM, Szydlo R, Horowitz, MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-2238.
8. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myeloid leukemia: a decision analysis. Ann Intern Med. 1997;127:1080-1088.
9. Hehlmann R, Hochhaus A, Kolb H-J, et al. Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely provided it is discontinued at least 90 days before the procedure. Blood. 1999;94:3668-3677.
10. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087-1092.
11. McGlave PB, Shu XU, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years experience of the National Marrow Donor Program. Blood. 2000;95: 2219-2225.
12. Craddock C, Szydlo RM, Dazzi F, et al. CMV serostatus is a major determinant of outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored GVHD prophylaxis. Br J Haematol. 2001;112:228-236.
13. Barrett AJ, Childs R. Non myeloablative stem cell transplants. Br J Haematol. 2000;111:6-17.
14. Champlin RE, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000; 111:18-29.
15. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med. 1996;2:561-566.
16. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
17. Hochhaus A, Reiter A, Saussele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood. 2000;95:62-66.